Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Intangibles: 2023-2024

Historic Intangibles for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $313.1 million.

  • Iovance Biotherapeutics' Intangibles was N/A to $335.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $335.3 million, marking a year-over-year change of. This contributed to the annual value of $313.1 million for FY2024, which is 30.85% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Intangibles stood at $313.1 million, which was up 30.85% from $239.3 million recorded in FY2023.
  • Iovance Biotherapeutics' Intangibles' 5-year high stood at $313.1 million during FY2024, with a 5-year trough of $239.3 million in FY2023.
  • For the 2-year period, Iovance Biotherapeutics' Intangibles averaged around $276.2 million, with its median value being $276.2 million (2023).
  • Data for Iovance Biotherapeutics' Intangibles shows a peak YoY skyrocketed of 30.85% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Intangibles (Yearly) stood at $239.3 million in 2023, then soared by 30.85% to $313.1 million in 2024.